Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome

Cancer Research

Volumn 73, Issue 10, 2013, Pages 2955-2964

  Hansen, Amanda G ^a   Freeman, Tanner J ^b   Arnold, Shanna A ^c   Starchenko, Alina ^b   Jones Paris, Celestial R ^c   Gilger, Michael A ^c   Washington, Mary K ^c,f   Fan, Kang Hsien ^e   Shyr, Yu ^e   Beauchamp, Robert D ^a,b,d,f   Zijlstra, Andries ^a,c,f,g  

^a Departments of Cancer Biology   (United States)

^b Cell and Developmental Biology   (United States)

^c Pathology   (United States)

^d Surgical Sciences ^*  (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

ANTIGENS, CD; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FETAL PROTEINS; HUMANS; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84877863177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2052     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J Clin 2011;61:212-36.
2. Compton CC. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-88. (Pubitemid 36443987)
3. Quasar Collaborative GroupGray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007;370:2020-9.
4. Figueredo A. Adjuvant therapy for stage II colon cancer: A systematic review from the cancer care ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22: 3395-407. (Pubitemid 41103699)
5. Midgley R, Kerr DJ. Adjuvant chemotherapy for stage II colorectal cancer: The time is right! Nat Clin Pract Oncol 2005;2:364-9.
6. Johnston PG. Stage II colorectal cancer: To treat or not to treat. Oncologist 2005;10:332-4. (Pubitemid 40647251)
7. Eschrich S. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526-35.
8. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
9. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009;27:4591-8.
10. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-90.
11. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, et al. Activated leukocyte cell adhesion molecule (CD166)-its prognostic power for colorectal cancer patients. J Surg Res 2012;177:e15-20.
12. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 2011;17:6934-43.
13. Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, et al. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology 2012;82:305-12.
14. Micciche F, Da Riva L, Fabbi M, Pilotti S, Mondellini P, Ferrini S, et al. Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors. PLoS ONE 2011;6:e17141.
15. Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res 2008;14:1726-33. (Pubitemid 351469457)
16. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer 2012;131: 396-405.
17. Hansen A, Swart GW, Zijlstra A. ALCAM. UCSD Nat Mol Pages 2011 Feb 1. doi:10.1038/mp.a004126.01.
18. Weichert W, Knösel T, Bellach J, Dietel M, Kristiansen G. ALCAM/ CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-4. (Pubitemid 39486521)
19. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-50.
20. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 2010;139:2072-82.e5.
21. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2002;54:34-43. (Pubitemid 36043834)
22. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205:359-76. (Pubitemid 40253926)
23. Davies SR, Dent C, Watkins G, King JA, Mokbel K, Jiang WG. Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep 2008;19:555-61. (Pubitemid 351176120)
24. Ishigami S, Ueno S, Arigami T, Arima H, Uchikado Y, Kita Y, et al. Clinical implication of CD166 expression in gastric cancer. J Surg Oncol 2011;103:57-61.
25. Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, et al. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. J Surg Res 2011;170:226-32.
26. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJF, Garbe C, Weidle UH, et al. Truncation of activated leukocyte cell adhesion molecule: A gateway to melanoma metastasis. J Invest Dermatol 2004;122:1293-301. (Pubitemid 38651106)
27. Swart GWM. Activated leukocyte cell adhesion molecule (CD166/ ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 2002;81:313-21. (Pubitemid 34692942)
28. Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, et al. Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol 2006;26: 5086-95. (Pubitemid 43955821)
29. Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, et al. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007;5:1246-53.
30. Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, Sauliunaite D, et al. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol 2010;101:564-9.
31. Zijlstra A. Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. Blood 2006;107:317-27. (Pubitemid 43053558)
32. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28:1248-1250.
33. Merchant NB, Voskresensky I, Rogers CM, LaFleur B, Dempsey PJ, Graves-Deal R, et al. TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008;14:1182-91. (Pubitemid 351302567)
34. Zhang T-C, ZhuW-G, HuangM-D, FanR-H, Chen X-F. Prognostic value of ADAM17 in human gastric cancer. Med Oncol 2012;29:2684-90.
35. Smedbakken L, Jensen JK, Hallen J, Atar D, Januzzi JL, Halvorsen B, et al. Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke 2011;42:2453-8.
36. Hollmen M,Maättä JA, Bald L, Sliwkowski MX, Elenius K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009;28:1309-19.
37. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 2009;101:457-64.
38. Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 2008; 112:419-27.
39. Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011;42:1946-52.
40. Piao D, Jiang T, Liu G, Wang B, Xu J, Zhu A. Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer. Mol Biol Rep 2012;39:661-8.